On August 29, 2012, shares of Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a company focused on pharmaceutical products for patients with renal disease, closed for the day's session at $2.06. Exactly two years later, on August 29, …
Keryx Biopharmaceuticals, Inc. KERX is expected to report first-quarter 2017 results on May 4. Last quarter, the company missed expectations by 18.52%. In fact, Keryx’s performance over the last four quarters has been disappointing. The …
I haven't exactly been a bull when it comes to Keryx Biopharmaceuticals (NASDAQ: KERX). For starters ... have provided all the warning I need to stay away from the stock. But things may be about to change. No, I'm still not interested in …
Keryx Biopharmaceuticals Inc. (NASDAQ: KERX) announced on Friday that it had received approval ... But the question is, even with successful clinical trials and FDA approval, why did the Keryx stock price fall so much after the approval?
INGN closed Tuesday's trading at $101.65, up 0.50%. In after-hours, the stock was up 5.76% to $107.50. Keryx Biopharmaceuticals Inc.'s (KERX) supplemental new drug application of Auryxia for the treatment of patients with iron …
Keryx Biopharmaceuticals (KERX) up 140% since last year Keryx Biopharmaceuticals (NASDAQ:KERX) saw its stock price shoot up 90% early last year when early testing showed Zerenex to be a promising drug with the potential to …
The ticker there is KERX. Campbell: What a weird story on Keryx. That's probably why we're interested in talking about it. Harjes: Yeah. The headline here is that they got a drug approved, and they reported earnings, and the stock slides 17%.
10/06 $KERX ALERT: New Keryx Biopharmaceuticals, Inc. SEC Filing From our Stock New.. 10/06 Keryx perks up ahead of FDA decision on expanded use of Auryxia; shares ahead.. 10/06 UPSIDE MOMENTUM ALERT: $KERX KERYX …